{
  "nctId": "NCT00791154",
  "briefTitle": "QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer",
  "officialTitle": "QUILT-2.013 A Phase 1b/2 Trial of AMG 479 or AMG 102 in Combination With Platinum-based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer",
  "protocolDocument": {
    "nctId": "NCT00791154",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2011-04-05",
    "uploadDate": "2024-04-17T13:43",
    "size": 2111935,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT00791154/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE1",
    "PHASE2"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "DOUBLE",
  "enrollmentInfo": {
    "enrollmentCount": 213,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2008-12-02",
    "completionDate": "2013-05-01",
    "primaryCompletionDate": "2010-02-02",
    "firstSubmitDate": "2008-10-23",
    "firstPostDate": "2008-11-14"
  },
  "eligibilityCriteria": {
    "criteria": "Key Inclusion Criteria\n\n* Histologically or cytologically confirmed SCLC\n* Extensive disease, defined by at least one of the following:\n* No limited disease (ie, no disease confined to the ipsilateral hemithorax, which can be safely encompassed within a tolerable radiation field)\n* Extrathoracic metastases\n* Malignant pericardial or pleural effusion\n* Contralateral hilar adenopathy\n* Measurable or nonmeasurable disease, as defined by modified RECIST\n* Eastern Cooperative Oncology Group (ECOG) status 0 or 1\n* ≥18 years old\n* Life expectancy (with therapy) ≥3 months\n* Adequate hematologic, hepatic, coagulation, renal, and metabolic function\n* Diabetes, if present, must be controlled, with glycosylated hemoglobin (HbA1C) ≤ 8% and fasting glucose levels ≤160 mg/dL\n\nKey Exclusion Criteria\n\n* Prior chemotherapy, chemoradiation, or investigational agent for SCLC\n* Prior radiotherapy to \\>25% of the bone marrow\n* Symptomatic or untreated central nervous system metastases (with exceptions)\n* Currently or previously treated with biologic, immunologic or other therapies for SCLC\n* Current serious or nonhealing wound or ulcer\n* History of prior concurrent other malignancy (with exceptions)\n* Thorombosis or vascular ischemic events within the last 12 months such as DVT, PE, TIA or MI\n* Any clinically significant medical condition other than cancer (eg, cardiovascular disease or COPD), which could interfere with the safe delivery of study treatment or risk of toxicity",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Overall Survival in Ganitumab Treated Subjects -Phase 2",
        "description": "The primary efficacy endpoint was overall survival, defined as time from randomization to death from any cause",
        "timeFrame": "Time from randomization to death from any cause, approximately 14 months"
      },
      {
        "measure": "Overall Survival in Rilotumumab Treated Subjects-Phase 2",
        "description": "The primary efficacy endpoint is overall survival, defined as time from randomization to death from any cause",
        "timeFrame": "Time from randomization to death from any cause, approximately 14 months"
      },
      {
        "measure": "Number of Subjects With Dose Limiting Toxicities-Phase 1",
        "description": "For Part 1, DLTs were defined as the incidence during the first 21 days of starting study treatment of any Grade 3 or higher hematologic or non-hematologic toxicity related to AMG 479 or AMG 102, or the combination of AMG 479 or AMG 102 with chemotherapy, except for lymphocytopenia and anemia. DLTs did not include fatigue, nausea, diarrhea, vomiting, hyperglycemia, neutropenia, thrombocytopenia, increased AST or ALT, or pulmonary embolism unless specific criteria were met as stated in protocol section 6.1.3.2.",
        "timeFrame": "First 21 days after start of study treatment"
      }
    ],
    "secondary": [],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 0,
      "totalCount": 1
    },
    "endpoints": {
      "primaryCount": 3,
      "secondaryCount": 0,
      "otherCount": 0,
      "totalCount": 3
    },
    "studyDesign": {
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 67,
    "complexityCategory": "Complex"
  },
  "collectionDate": "2025-09-22T02:30:52.660Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}